Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 72


Virus-specific memory T cells populate tumors and can be repurposed for tumor immunotherapy.

Rosato PC, Wijeyesinghe S, Stolley JM, Nelson CE, Davis RL, Manlove LS, Pennell CA, Blazar BR, Chen CC, Geller MA, Vezys V, Masopust D.

Nat Commun. 2019 Feb 4;10(1):567. doi: 10.1038/s41467-019-08534-1.


A patient-centered mobile health application to motivate use of genetic counseling among women with ovarian cancer: A pilot randomized controlled trial.

Vogel RI, Niendorf K, Petzel S, Lee H, Teoh D, Blaes AH, Argenta P, Rivard C, Winterhoff B, Lee HY, Geller MA.

Gynecol Oncol. 2019 Feb 1. pii: S0090-8258(19)30062-9. doi: 10.1016/j.ygyno.2019.01.019. [Epub ahead of print]


Simultaneous Measurement of 92 Serum Protein Biomarkers for the Development of a Multi-Protein Classifier for Ovarian Cancer Detection.

Skubitz AP, Boylan KL, Geschwind KA, Cao Q, Starr TK, Geller MA, Celestino J, Bast RC, Lu KH, Koopmeiners JS.

Cancer Prev Res (Phila). 2019 Feb 1. pii: canprevres.0221.2018. doi: 10.1158/1940-6207.CAPR-18-0221. [Epub ahead of print]


Non-human Papillomavirus Cervical Mucinous Adenocarcinoma in a Phenotypic Male with Congenital Adrenal Hyperplasia.

Heim J, Dickson E, Geller MA, Rivard C.

Cureus. 2018 Nov 18;10(11):e3607. doi: 10.7759/cureus.3607.


Cytokine-induced memory-like natural killer cells have enhanced function, proliferation, and in vivo expansion against ovarian cancer cells.

Uppendahl LD, Felices M, Bendzick L, Ryan C, Kodal B, Hinderlie P, Boylan KLM, Skubitz APN, Miller JS, Geller MA.

Gynecol Oncol. 2019 Jan 15. pii: S0090-8258(19)30039-3. doi: 10.1016/j.ygyno.2019.01.006. [Epub ahead of print]


Nomogram for Predicting Individual Survival After Recurrence of Advanced-Stage, High-Grade Ovarian Carcinoma.

Rose PG, Java JJ, Salani R, Geller MA, Secord AA, Tewari KS, Bender DP, Mutch DG, Friedlander ML, Van Le L, Method MW, Hamilton CA, Lee RB, Wenham RM, Guntupalli SR, Markman M, Muggia FM, Armstrong DK, Bookman MA, Burger RA, Copeland LJ.

Obstet Gynecol. 2019 Feb;133(2):245-254. doi: 10.1097/AOG.0000000000003086.


Corrigendum to "Single cell sequencing reveals heterogeneity within ovarian cancer epithelium and cancer associated stromal cells" [Gyncol. Oncol. 144 (2017) 598-606].

Winterhoff BJ, Maile M, Mitra AK, Sebe A, Bazzaro M, Geller MA, Abrahante JE, Klein M, Hellweg R, Mullany SA, Beckman K, Daniel J, Starr TK.

Gynecol Oncol. 2018 Oct;151(1):182-186. doi: 10.1016/j.ygyno.2018.07.015. Epub 2018 Aug 7. No abstract available.


A qualitative study of barriers to genetic counseling and potential for mobile technology education among women with ovarian cancer.

Vogel RI, Niendorf K, Lee H, Petzel S, Lee HY, Geller MA.

Hered Cancer Clin Pract. 2018 Jul 4;16:13. doi: 10.1186/s13053-018-0095-z. eCollection 2018.


Effects of web-based instruction and patient preferences on patient-reported outcomes and learning for women with advanced ovarian cancer: A randomized controlled trial.

Petzel SV, Isaksson Vogel R, Cragg J, McClellan M, Chan D, Jacko JA, Sainfort F, Geller MA.

J Psychosoc Oncol. 2018 Jul-Aug;36(4):503-519. doi: 10.1080/07347332.2018.1457125. Epub 2018 May 23.


Excess Cost of Cervical Cancer Screening Beyond Recommended Screening Ages or After Hysterectomy in a Single Institution.

Teoh D, Hultman G, DeKam M, Isaksson Vogel R, Downs LS Jr, Geller MA, Le C, Melton G, Kulasingam S.

J Low Genit Tract Dis. 2018 Jul;22(3):184-188. doi: 10.1097/LGT.0000000000000400.


Continuous treatment with IL-15 exhausts human NK cells via a metabolic defect.

Felices M, Lenvik AJ, McElmurry R, Chu S, Hinderlie P, Bendzick L, Geller MA, Tolar J, Blazar BR, Miller JS.

JCI Insight. 2018 Feb 8;3(3). pii: 96219. doi: 10.1172/jci.insight.96219. [Epub ahead of print]


Assessment of Circulating Tumor Cells as a Predictive Biomarker of Histology in Women With Suspected Ovarian Cancer.

Lou E, Vogel RI, Teoh D, Hoostal S, Grad A, Gerber M, Monu M, Lukaszewski T, Deshpande J, Linden MA, Geller MA.

Lab Med. 2018 Mar 21;49(2):134-139. doi: 10.1093/labmed/lmx084.


Natural Killer Cell-Based Immunotherapy in Gynecologic Malignancy: A Review.

Uppendahl LD, Dahl CM, Miller JS, Felices M, Geller MA.

Front Immunol. 2018 Jan 5;8:1825. doi: 10.3389/fimmu.2017.01825. eCollection 2017. Review.


Clinicopathologic characteristics associated with long-term survival in advanced epithelial ovarian cancer: an NRG Oncology/Gynecologic Oncology Group ancillary data study.

Hamilton CA, Miller A, Casablanca Y, Horowitz NS, Rungruang B, Krivak TC, Richard SD, Rodriguez N, Birrer MJ, Backes FJ, Geller MA, Quinn M, Goodheart MJ, Mutch DG, Kavanagh JJ, Maxwell GL, Bookman MA.

Gynecol Oncol. 2018 Feb;148(2):275-280. doi: 10.1016/j.ygyno.2017.11.018. Epub 2017 Nov 28.


An NRG Oncology/GOG study of molecular classification for risk prediction in endometrioid endometrial cancer.

Cosgrove CM, Tritchler DL, Cohn DE, Mutch DG, Rush CM, Lankes HA, Creasman WT, Miller DS, Ramirez NC, Geller MA, Powell MA, Backes FJ, Landrum LM, Timmers C, Suarez AA, Zaino RJ, Pearl ML, DiSilvestro PA, Lele SB, Goodfellow PJ.

Gynecol Oncol. 2018 Jan;148(1):174-180. doi: 10.1016/j.ygyno.2017.10.037. Epub 2017 Nov 11.


A multiplex platform for the identification of ovarian cancer biomarkers.

Boylan KLM, Geschwind K, Koopmeiners JS, Geller MA, Starr TK, Skubitz APN.

Clin Proteomics. 2017 Oct 10;14:34. doi: 10.1186/s12014-017-9169-6. eCollection 2017.


Surgical outcomes among elderly women with endometrial cancer treated by laparoscopic hysterectomy: a NRG/Gynecologic Oncology Group study.

Bishop EA, Java JJ, Moore KN, Spirtos NM, Pearl ML, Zivanovic O, Kushner DM, Backes F, Hamilton CA, Geller MA, Hurteau J, Mathews C, Wenham RM, Ramirez PT, Zweizig S, Walker JL.

Am J Obstet Gynecol. 2018 Jan;218(1):109.e1-109.e11. doi: 10.1016/j.ajog.2017.09.026. Epub 2017 Oct 14.


Gene expression markers of Tumor Infiltrating Leukocytes.

Danaher P, Warren S, Dennis L, D'Amico L, White A, Disis ML, Geller MA, Odunsi K, Beechem J, Fling SP.

J Immunother Cancer. 2017 Feb 21;5:18. doi: 10.1186/s40425-017-0215-8. eCollection 2017.


IL-15 super-agonist (ALT-803) enhances natural killer (NK) cell function against ovarian cancer.

Felices M, Chu S, Kodal B, Bendzick L, Ryan C, Lenvik AJ, Boylan KLM, Wong HC, Skubitz APN, Miller JS, Geller MA.

Gynecol Oncol. 2017 Jun;145(3):453-461. doi: 10.1016/j.ygyno.2017.02.028. Epub 2017 Feb 22.


Ectodomain shedding of the cell adhesion molecule Nectin-4 in ovarian cancer is mediated by ADAM10 and ADAM17.

Buchanan PC, Boylan KLM, Walcheck B, Heinze R, Geller MA, Argenta PA, Skubitz APN.

J Biol Chem. 2017 Apr 14;292(15):6339-6351. doi: 10.1074/jbc.M116.746859. Epub 2017 Feb 23.


Single Health System Adherence to 2012 Cervical Cancer Screening Guidelines at Extremes of Age and Posthysterectomy.

Teoh D, Isaksson Vogel R, Hultman G, Monu M, Downs L, Geller MA, Le C, Melton-Meaux G, Kulasingam S.

Obstet Gynecol. 2017 Mar;129(3):448-456. doi: 10.1097/AOG.0000000000001895.


Single cell sequencing reveals heterogeneity within ovarian cancer epithelium and cancer associated stromal cells.

Winterhoff BJ, Maile M, Mitra AK, Sebe A, Bazzaro M, Geller MA, Abrahante JE, Klein M, Hellweg R, Mullany SA, Beckman K, Daniel J, Starr TK.

Gynecol Oncol. 2017 Mar;144(3):598-606. doi: 10.1016/j.ygyno.2017.01.015. Epub 2017 Jan 19. Erratum in: Gynecol Oncol. 2018 Oct;151(1):182-186.


Enhanced Recovery Program and Length of Stay After Laparotomy on a Gynecologic Oncology Service: A Randomized Controlled Trial.

Dickson EL, Stockwell E, Geller MA, Vogel RI, Mullany SA, Ghebre R, Witherhoff BJ, Downs LS Jr, Carson LF, Teoh D, Glasgow M, Gerber M, Rivard C, Erickson BK, Hutchins J, Argenta PA.

Obstet Gynecol. 2017 Feb;129(2):355-362. doi: 10.1097/AOG.0000000000001838.


Modeling the QBO-Improvements resulting from higher-model vertical resolution.

Geller MA, Zhou T, Shindell D, Ruedy R, Aleinov I, Nazarenko L, Tausnev NL, Kelley M, Sun S, Cheng Y, Field RD, Faluvegi G.

J Adv Model Earth Syst. 2016 Sep;8(3):1092-1105. Epub 2016 Jul 13.


The effect of photobiomodulation on chemotherapy-induced peripheral neuropathy: A randomized, sham-controlled clinical trial.

Argenta PA, Ballman KV, Geller MA, Carson LF, Ghebre R, Mullany SA, Teoh DG, Winterhoff BJ, Rivard CL, Erickson BK.

Gynecol Oncol. 2017 Jan;144(1):159-166. doi: 10.1016/j.ygyno.2016.11.013. Epub 2016 Nov 22.


Long term follow-up of a phase II trial of multimodal therapy given in a "sandwich" method for stage III, IV, and recurrent endometrial cancer.

Glasgow M, Vogel RI, Burgart J, Argenta P, Dusenbery K, Geller MA.

Gynecol Oncol Res Pract. 2016 May 26;3:6. doi: 10.1186/s40661-016-0027-4. eCollection 2016.


A model for patient-direct screening and referral for familial cancer risk.

Niendorf KB, Geller MA, Vogel RI, Church TR, Leininger A, Bakke A, Madoff RD.

Fam Cancer. 2016 Oct;15(4):707-16. doi: 10.1007/s10689-016-9912-6.


Clinicopathologic Significance of Mismatch Repair Defects in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study.

McMeekin DS, Tritchler DL, Cohn DE, Mutch DG, Lankes HA, Geller MA, Powell MA, Backes FJ, Landrum LM, Zaino R, Broaddus RD, Ramirez N, Gao F, Ali S, Darcy KM, Pearl ML, DiSilvestro PA, Lele SB, Goodfellow PJ.

J Clin Oncol. 2016 Sep 1;34(25):3062-8. doi: 10.1200/JCO.2016.67.8722. Epub 2016 Jun 20.


Tunneling nanotube formation is stimulated by hypoxia in ovarian cancer cells.

Desir S, Dickson EL, Vogel RI, Thayanithy V, Wong P, Teoh D, Geller MA, Steer CJ, Subramanian S, Lou E.

Oncotarget. 2016 Jul 12;7(28):43150-43161. doi: 10.18632/oncotarget.9504.


Designing an Educational Website to Improve Quality of Supportive Oncology Care for Women with Ovarian Cancer: An Expert Usability Review and Analysis.

McClellan MA, Karumur RP, Vogel RI, Petzel SV, Cragg J, Chan D, Jacko JA, Sainfort F, Geller MA.

Int J Hum Comput Interact. 2016;32(4):297-307. Epub 2016 Jan 11.


Combined Microsatellite Instability, MLH1 Methylation Analysis, and Immunohistochemistry for Lynch Syndrome Screening in Endometrial Cancers From GOG210: An NRG Oncology and Gynecologic Oncology Group Study.

Goodfellow PJ, Billingsley CC, Lankes HA, Ali S, Cohn DE, Broaddus RJ, Ramirez N, Pritchard CC, Hampel H, Chassen AS, Simmons LV, Schmidt AP, Gao F, Brinton LA, Backes F, Landrum LM, Geller MA, DiSilvestro PA, Pearl ML, Lele SB, Powell MA, Zaino RJ, Mutch D.

J Clin Oncol. 2015 Dec 20;33(36):4301-8. doi: 10.1200/JCO.2015.63.9518. Epub 2015 Nov 9.


Induced Pluripotent Stem Cell-Derived Natural Killer Cells for Treatment of Ovarian Cancer.

Hermanson DL, Bendzick L, Pribyl L, McCullar V, Vogel RI, Miller JS, Geller MA, Kaufman DS.

Stem Cells. 2016 Jan;34(1):93-101. doi: 10.1002/stem.2230. Epub 2015 Dec 6.


A multi-institutional study of outcomes in stage I-III uterine carcinosarcoma.

Dickson EL, Vogel RI, Gehrig PA, Pierce S, Havrilesky L, Secord AA, Dottino J, Fader AN, Ricci S, Geller MA.

Gynecol Oncol. 2015 Nov;139(2):275-82. doi: 10.1016/j.ygyno.2015.09.002. Epub 2015 Sep 6.


Abdominal Hysterectomy: Reduced Risk of Surgical Site Infection Associated with Robotic and Laparoscopic Technique.

Colling KP, Glover JK, Statz CA, Geller MA, Beilman GJ.

Surg Infect (Larchmt). 2015 Oct;16(5):498-503. doi: 10.1089/sur.2014.203. Epub 2015 Jun 12.


Ultrasound guided subcostal transversus abdominis plane (TAP) infiltration with liposomal bupivacaine for patients undergoing robotic assisted hysterectomy: A prospective randomized controlled study.

Hutchins J, Delaney D, Vogel RI, Ghebre RG, Downs LS Jr, Carson L, Mullany S, Teoh D, Geller MA.

Gynecol Oncol. 2015 Sep;138(3):609-13. doi: 10.1016/j.ygyno.2015.06.008. Epub 2015 Jun 6.


Propensity-Weighted Comparison of Long-Term Risk of Urinary Adverse Events in Elderly Women Treated For Cervical Cancer.

Elliott SP, Fan Y, Jarosek S, Chu H, Downs L, Dusenbery K, Geller MA, Virnig BA.

Int J Radiat Oncol Biol Phys. 2015 Jul 1;92(3):586-93. doi: 10.1016/j.ijrobp.2015.02.025. Epub 2015 Apr 16.


Ultrasound-guided subcostal transversus abdominis plane infiltration with liposomal bupivacaine for patients undergoing robotic-assisted hysterectomy: a retrospective study.

Hutchins J, Vogel RI, Ghebre R, McNally A, Downs LS Jr, Gryzmala E, Geller MA.

Int J Gynecol Cancer. 2015 Jun;25(5):937-41. doi: 10.1097/IGC.0000000000000429.


Bariatric surgery-induced weight loss changes immune markers in the endometrium of morbidly obese women.

Linkov F, Elishaev E, Gloyeske N, Edwards R, Althouse AD, Geller MA, Svendsen C, Argenta PA.

Surg Obes Relat Dis. 2014 Sep-Oct;10(5):921-6. doi: 10.1016/j.soard.2014.03.023. Epub 2014 Apr 19.


A feasibility study to identify proteins in the residual Pap test fluid of women with normal cytology by mass spectrometry-based proteomics.

Boylan KL, Afiuni-Zadeh S, Geller MA, Hickey K, Griffin TJ, Pambuccian SE, Skubitz AP.

Clin Proteomics. 2014 Jul 14;11(1):30. doi: 10.1186/1559-0275-11-30. eCollection 2014.


Improving referral for genetic risk assessment in ovarian cancer using an electronic medical record system.

Petzel SV, Vogel RI, McNiel J, Leininger A, Argenta PA, Geller MA.

Int J Gynecol Cancer. 2014 Jul;24(6):1003-9. doi: 10.1097/IGC.0000000000000148.


Hormone receptor expression patterns in the endometrium of asymptomatic morbidly obese women before and after bariatric surgery.

Argenta P, Svendsen C, Elishaev E, Gloyeske N, Geller MA, Edwards RP, Linkov F.

Gynecol Oncol. 2014 Apr;133(1):78-82. doi: 10.1016/j.ygyno.2013.12.005.


Cervical cytology and multiple type HPV infection: a study of 8182 women ages 31-65.

Dickson EL, Vogel RI, Geller MA, Downs LS Jr.

Gynecol Oncol. 2014 Jun;133(3):405-8. doi: 10.1016/j.ygyno.2014.03.552. Epub 2014 Mar 20.


Intraperitoneal delivery of human natural killer cells for treatment of ovarian cancer in a mouse xenograft model.

Geller MA, Knorr DA, Hermanson DA, Pribyl L, Bendzick L, McCullar V, Miller JS, Kaufman DS.

Cytotherapy. 2013 Oct;15(10):1297-306. doi: 10.1016/j.jcyt.2013.05.022.


Development and pilot of an advance care planning website for women with ovarian cancer: a randomized controlled trial.

Vogel RI, Petzel SV, Cragg J, McClellan M, Chan D, Dickson E, Jacko JA, Sainfort F, Geller MA.

Gynecol Oncol. 2013 Nov;131(2):430-6. doi: 10.1016/j.ygyno.2013.08.017. Epub 2013 Aug 27.


Predicting response to the anti-estrogen fulvestrant in recurrent ovarian cancer.

Argenta PA, Um I, Kay C, Harrison D, Faratian D, Sueblinvong T, Geller MA, Langdon SP.

Gynecol Oncol. 2013 Nov;131(2):368-73. doi: 10.1016/j.ygyno.2013.07.099. Epub 2013 Jul 30.


Genetic risk assessment for women with epithelial ovarian cancer: referral patterns and outcomes in a university gynecologic oncology clinic.

Petzel SV, Vogel RI, Bensend T, Leininger A, Argenta PA, Geller MA.

J Genet Couns. 2013 Oct;22(5):662-73. doi: 10.1007/s10897-013-9598-y. Epub 2013 May 16.


Hyperthermic intraperitoneal chemotherapy with carboplatin for optimally-cytoreduced, recurrent, platinum-sensitive ovarian carcinoma: a pilot study.

Argenta PA, Sueblinvong T, Geller MA, Jonson AL, Downs LS Jr, Carson LF, Ivy JJ, Judson PL.

Gynecol Oncol. 2013 Apr;129(1):81-5. doi: 10.1016/j.ygyno.2013.01.010. Epub 2013 Jan 23.


A multicenter evaluation of adjuvant therapy in women with optimally resected stage IIIC endometrial cancer.

Secord AA, Geller MA, Broadwater G, Holloway R, Shuler K, Dao NY, Gehrig PA, O'Malley DM, Finkler N, Havrilesky LJ.

Gynecol Oncol. 2013 Jan;128(1):65-70. doi: 10.1016/j.ygyno.2012.10.010. Epub 2012 Oct 17.


Use of allogeneic NK cells for cancer immunotherapy.

Geller MA, Miller JS.

Immunotherapy. 2011 Dec;3(12):1445-59. doi: 10.2217/imt.11.131. Review.


A prospective, randomized trial of integrative medicine for women with ovarian cancer.

Judson PL, Dickson EL, Argenta PA, Xiong Y, Geller MA, Carson LF, Ghebre R, Jonson AL, Downs LS Jr.

Gynecol Oncol. 2011 Nov;123(2):346-50. doi: 10.1016/j.ygyno.2011.07.099. Epub 2011 Aug 23.

Supplemental Content

Loading ...
Support Center